A Phase 3 interventional study of Fostamatinib Disodium in Immune Thrombocytopenic Purpura, sponsored by Rigel Pharmaceuticals. Completed at 55 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Rigel Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom — 7 open to participants now, 12 under way, 8 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United Kingdom.
Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom, this one is the 13th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2014, is one of 23 in phase 3, and was the 11th registered.
505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →7 of the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom are open now. Recruiting first, the newest first:
Gliknik Inc. · Sites in United Kingdom
Ages 18–80
Incyte Corporation · Sites in United Kingdom, United States, Australia and 4 more countries
Ages 18+
argenx · Sites in United Kingdom, France, Germany and 7 more countries
Ages 12–17
Takeda · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18+
Eli Lilly and Company · Sites in United Kingdom, United States, China and 7 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 24
First in 2004; this study’s year is marked. 5 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 58 across 378 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 72 across the 46 interventional studies, 148 across the 4 observational. Of the 37 that completed or were terminated, 22 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 50 have an industry lead sponsor. The 10 most frequent:
Rigel Pharmaceuticals is the lead sponsor of 28 studies on the registry; 5 are open to participants now.
Rigel Pharmaceuticals has 6 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
2 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04812925Phase 3argenxA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | 2027-10 |
| NCT07104565Incyte CorporationStudy to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | 2027-09-23 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
Drug: Fostamatinib Disodium
Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
Also known as: R935788, R788, Fostamatinib
Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version 1
Percentage of subjects who achieved platelet count of at least 50,000/µL within 12 Weeks of beginning treatment up to 12 months was analyzed among all subjects who received active treatment in one of the prior studies (C788-047 or C788-048), in the current extension study (C788-049), or in both prior and current studies. Treated Population was defined as all enrolled and treated subjects.
Time frame: Up to 12 months
Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Placebo in 047/048 and Fostamatinib 049): Version 2
A within-subject, between-study comparison of platelet counts for subjects who were previously treated with placebo in one of the prior studies (C788-047 or C788-048) was prospectively defined in the protocol (version 2). Achievement of platelet response by 12 weeks and maintenance of platelet response for 12 weeks was analyzed among subjects who had been randomized to placebo in one of the prior studies (C788-047 or C788-048). Treated Population was defined as all enrolled and treated subjects.
Time frame: Up to 12 months
Duration of Platelet Response Based on Platelet Count and Rescue Medication
The duration of platelet response was defined as the time from when the subject first achieved a platelet count of at least 50,000/µL, until the first of 2 visits with platelet counts \< 50,000/µL that were at least 4 weeks apart without an intervening visit with a platelet count less than equal to (\<=) 50,000/µL unrelated to rescue therapy. Duration of platelet response was analyzed using the Kaplan-Meier method. Treated Population was defined as all enrolled and treated subjects. Here, a number of subjects analyzed included all subjects evaluable for this endpoint.
Time frame: Up to 12 months
Percentage of Subjects in Whom a Reduction in the Dose of Concomitant ITP Therapy Can be Achieved While Maintaining an Adequate Platelet Count
The percentage of subjects in whom a reduction in the dose of concomitant ITP therapy could be achieved while maintaining an adequate platelet count, the reduction event was clarified to apply only to reductions in the dose of concomitant ITP therapy occurring within a period of platelet response and the reduction event was not be prompted by an adverse event.
Time frame: Up to 12 months
A total of 124 subjects were screened from studies C788-047/ C788-048 for this extension study. Out of which, 123 subjects were enrolled and treated with study drug.
| Milestone | Fostamatinib Disodium |
|---|---|
| Started | 123 |
| Completed | 29 |
| Not completed | 94 |
Percentage of subjects who achieved platelet count of at least 50,000/µL within 12 Weeks of beginning treatment up to 12 months was analyzed among all subjects who received active treatment in one of the prior studies (C788-047 or C788-048), in the current extension study (C788-049), or in both prior and current studies. Treated Population was defined as all enrolled and treated subjects.
| Percentage of Subjects | Fostamatinib Disodium |
|---|---|
| Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version 1 | 15.4 (9.6 to 23.1) |
A within-subject, between-study comparison of platelet counts for subjects who were previously treated with placebo in one of the prior studies (C788-047 or C788-048) was prospectively defined in the protocol (version 2). Achievement of platelet response by 12 weeks and maintenance of platelet response for 12 weeks was analyzed among subjects who had been randomized to placebo in one of the prior studies (C788-047 or C788-048). Treated Population was defined as all enrolled and treated subjects.
| Percentage of Subjects | Fostamatinib Disodium |
|---|---|
| Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Placebo in 047/048 and Fostamatinib 049): Version 2 | 2.3 (0.1 to 12.0) |
The duration of platelet response was defined as the time from when the subject first achieved a platelet count of at least 50,000/µL, until the first of 2 visits with platelet counts \< 50,000/µL that were at least 4 weeks apart without an intervening visit with a platelet count less than equal to (\<=) 50,000/µL unrelated to rescue therapy. Duration of platelet response was analyzed using the Kaplan-Meier method. Treated Population was defined as all enrolled and treated subjects. Here, a number of subjects analyzed included all subjects evaluable for this endpoint.
| Days | Fostamatinib Disodium |
|---|---|
| Duration of Platelet Response Based on Platelet Count and Rescue Medication | 127.0 (71.0 to 483.0) |
The percentage of subjects in whom a reduction in the dose of concomitant ITP therapy could be achieved while maintaining an adequate platelet count, the reduction event was clarified to apply only to reductions in the dose of concomitant ITP therapy occurring within a period of platelet response and the reduction event was not be prompted by an adverse event.
No measurements were reported for this outcome.
Collected over Baseline up to 62 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fostamatinib Disodium | 4/123 (3.3%) | 34/123 (27.6%) | 98/123 (79.7%) |
| Event | Fostamatinib Disodium |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 8/123 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/123 |
| Transaminases increasedInvestigations | 2/123 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 2/123 |
| SepsisInfections and infestations | 2/123 |
| Aortic stenosisVascular disorders | 1/123 |
| Chest painGeneral disorders | 1/123 |
| Mucosal haemorrhageGeneral disorders | 1/123 |
| PyrexiaGeneral disorders | 1/123 |
| MenorrhagiaReproductive system and breast disorders | 1/123 |
| Event | Fostamatinib Disodium |
|---|---|
| DiarrhoeaGastrointestinal disorders | 36/123 |
| HypertensionVascular disorders | 22/123 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 19/123 |
| PetechiaeSkin and subcutaneous tissue disorders | 19/123 |
| HeadacheNervous system disorders | 15/123 |
| Upper respiratory tract infectionInfections and infestations | 14/123 |
| DizzinessNervous system disorders | 13/123 |
| ContusionInjury, poisoning and procedural complications | 12/123 |
| VomitingGastrointestinal disorders | 11/123 |
| NauseaGastrointestinal disorders | 11/123 |
Baseline characteristics are analyzed with treated population data analysis set which was defined as all enrolled and treated subjects.
| Age, Continuous(years) | Overall Study |
|---|---|
| Median | 52.0 (20 to 88) |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 74 |
| Male | 49 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 121 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 113 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(Participants) | Overall Study |
|---|---|
| Romania | 1 |
| Hungary | 2 |
| United States | 17 |
| Czechia | 10 |
| United Kingdom | 18 |
| Spain | 4 |
| Canada | 4 |
| Austria | 1 |
| Netherlands | 1 |
| Norway | 2 |
| Poland | 34 |
| Denmark | 1 |
| Italy | 6 |
| Bulgaria | 12 |
| Australia | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Oct 2014, a primary completion of Jun 2020 and a completion of Jun 2020. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2023, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fostamatinib
Purpura, Thrombocytopenic, Idiopathic →